Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

"By deploying AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time," said Alex Zhavoronkov, founder and CEO of Insilico Medicine. Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery | Reuters Lilly and Insilico had signed a research collaboration in November, broadening a partnership that began with an AI-based software licensing agreement in 2023. Excl ...